FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Veterinary research communications2022; 47(2); 473-485; doi: 10.1007/s11259-022-09964-x

In vitro and in vivo evaluation of kinase and protease inhibitors against Trypanosoma evansi.

Abstract: Trypanosoma evansi is a causative agent of chronic wasting and fatal disease of livestock and wild animals known as surra. In this study, repurposing approach based on drug target was used to investigate the efficacy of kinase inhibitors (Barasertib-HQPA, BAR and Palbociclib isethionate, PAL) and protease inhibitors (Z-pro-prolinal, Z-PRO and Leupeptin hemisulphate, LEU) against T. evansi in HMI-9 medium. BAR, PAL and Z-PRO exhibited IC values of 13.52 µM, 0.6375 µM and 63.20 µM against T. evansi in terms of growth inhibition, in the contrary, LEU failed to exhibit a significant growth inhibition at any time interval. Furthermore, oligopeptidase B and aurora kinase genes of T. evansi were targeted to determine the effect of these drugs on quantitative mRNA expression, which showed significant (p < 0.01) up-regulation of both genes in the BAR and PAL-exposed population at 12 h of exposure, whereas, Z-PRO showed only significant (p < 0.05) up-regulation of aurora kinase gene at 12 h interval. In cytotoxicity assay, BAR exhibited 52% and 41% cytotoxicity at 50 μM concentration (about five folds the IC value on equine PBMC's and Vero cell line, respectively. Similarly, the cytotoxicity of 25% and 24% were recorded at 10 μM concentration (about ten folds to the IC value) of PAL in equine PBMC's and Vero cell line, respectively. Of these, BAR and PAL, which were found effective under in vitro trials, raised the longevity of mice at higher doses during in vivo trials. Data generated showed that kinase inhibitors have higher potential to explore therapeutic molecules against surra organism.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.
Get Full Text
Publication Date: 2022-06-25 PubMed ID: 35751782PubMed Central: 3789323DOI: 10.1007/s11259-022-09964-xGoogle Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This study investigates the effectiveness of various kinase and protease inhibitors in combating Trypanosoma evansi, a harmful parasite causing fatal disease in livestock and wild animals. The findings suggest that some of these inhibitors could potentially serve as therapeutic agents against the parasite.

Background

  • Trypanosoma evansi is a parasite causing surra, a fatal disease in animals that can lead to chronic wasting.
  • Kinase and protease inhibitors are often used in the treatment of cancer and other diseases. This study explores if they can also be effective against T. evansi.

Experiment and Results

  • The researchers examined different inhibitors (Barasertib-HQPA – BAR, Palbociclib isethionate – PAL, Z-pro-prolinal – Z-PRO, and Leupeptin hemisulphate – LEU) for their efficacy against T. evansi within a specific growth medium.
  • BAR, PAL, and Z-PRO inhibited the growth of the parasite to varying degrees, while LEU showed no significant inhibitory effect.
  • The researchers analyzed the quantities of specific T. evansi genes (oligopeptidase B and aurora kinase) to determine how the drugs affected them. Significant upregulation of these genes was observed in populations exposed to BAR and PAL.

Cytotoxicity Assay

  • An assay was performed to determine the cytotoxic effect of the inhibitors on equine PBMC’s and Vero cell lines.
  • BAR showed 52% and 41% cytotoxicity at 50 µM concentration (about five folds the IC value) on equine PBMC’s and Vero cell line, respectively.
  • The cytotoxicity of 25% and 24% was recorded at 10 µM concentration (about ten folds to the IC value) of PAL in equine PBMC’s and Vero cell line, respectively.

In Vivo Trials

  • BAR and PAL, noted as effective in the in-vitro trials were test on mice. The results showed these compounds increased the lifespan of infected mice at higher doses.

Conclusion

  • The study reveals that kinase inhibitors, in particular, have a promising potential as therapeutic agents against the parasite T. evansi.

Cite This Article

APA
Bhutia WD, Gupta S, Rani R, Batra K, Sethi K, Kumar S, Kumar R. (2022). In vitro and in vivo evaluation of kinase and protease inhibitors against Trypanosoma evansi. Vet Res Commun, 47(2), 473-485. https://doi.org/10.1007/s11259-022-09964-x

Publication

Veterinary research communications
ISSN: 1573-7446
NlmUniqueID: 8100520
Country: Switzerland
Language: English
Volume: 47
Issue: 2
Pages: 473-485

Researcher Affiliations

Bhutia, Wangchuk Dorjee
  • Parasitology Lab, ICAR-National Research Centre on Equines, Hisar, Haryana, 125001, India.
Gupta, Snehil
  • Department of Veterinary Parasitology, Lala Lajpat Rai University of Veterinary and Animal Sciences, Hisar, Haryana, 125001, India.
Rani, Ruma
  • Parasitology Lab, ICAR-National Research Centre on Equines, Hisar, Haryana, 125001, India.
Batra, Kanisht
  • Department of Animal Biotechnology, Lala Lajpat Rai University of Veterinary and Animal Sciences, Hisar, Haryana, 125001, India.
Sethi, Khushboo
  • Parasitology Lab, ICAR-National Research Centre on Equines, Hisar, Haryana, 125001, India.
Kumar, Sanjay
  • Parasitology Lab, ICAR-National Research Centre on Equines, Hisar, Haryana, 125001, India.
Kumar, Rajender
  • Parasitology Lab, ICAR-National Research Centre on Equines, Hisar, Haryana, 125001, India. rkg.nrce@gmail.com.

MeSH Terms

  • Animals
  • Horses
  • Mice
  • Protease Inhibitors
  • Leukocytes, Mononuclear
  • Trypanosoma
  • Animals, Wild
  • Aurora Kinases

Grant Funding

  • F. No. F No. 3(1)/2020-Budget- NRCE sub-scheme / Indian Council of Agriculture Research

References

This article includes 31 references
  1. Bossard G, Cuny G, Geiger A. Secreted proteases of Trypanosoma brucei gambiense: possible targets for sleeping sickness control?. Biofactors 2013 Jul-Aug;39(4):407-14.
    doi: 10.1002/biof.1100pubmed: 23553721google scholar: lookup
  2. Brenndörfer M, Boshart M. Selection of reference genes for mRNA quantification in Trypanosoma brucei.. Mol Biochem Parasitol 2010 Jul;172(1):52-5.
    doi: 10.1016/j.molbiopara.2010.03.007pubmed: 20302889google scholar: lookup
  3. Burleigh BA, Caler EV, Webster P, Andrews NW. A cytosolic serine endopeptidase from Trypanosoma cruzi is required for the generation of Ca2+ signaling in mammalian cells.. J Cell Biol 36:609–620.
    doi: 10.1083/jcb.136.3.609google scholar: lookup
  4. Coetzer TH, Goldring JP, Huson LE. Oligopeptidase B: a processing peptidase involved in pathogenesis.. Biochimie 2008 Feb;90(2):336-44.
    doi: 10.1016/j.biochi.2007.10.011pubmed: 18029266google scholar: lookup
  5. Desquesnes M, Dargantes A, Lai DH, Lun ZR, Holzmuller P, Jittapalapong S. Trypanosoma evansi and surra: a review and perspectives on transmission, epidemiology and control, impact, and zoonotic aspects.. Biomed Res Int 2013;2013:321237.
    doi: 10.1155/2013/194176pubmed: 24151595pmc: 3789323google scholar: lookup
  6. Finelle P. African animal trypanosomiasis.. World Animal Review 37:1–7.
  7. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.. Mol Cancer Ther 2004 Nov;3(11):1427-38.
    doi: 10.1158/1535-7163.1427.3.11pubmed: 15542782google scholar: lookup
  8. Geiger A, Simo G, Grébaut P, Peltier JB, Cuny G, Holzmuller P. Transcriptomics and proteomics in human African trypanosomiasis: current status and perspectives.. J Proteomics 2011 Aug 24;74(9):1625-43.
    doi: 10.1016/j.jprot.2011.01.016pubmed: 21316496google scholar: lookup
  9. Hammarton TC. Cell cycle regulation in Trypanosoma brucei.. Mol Biochem Parasitol 2007 May;153(1):1-8.
    doi: 10.1016/j.molbiopara.2007.01.017pubmed: 17335918pmc: 1914216google scholar: lookup
  10. Jones NG, Thomas EB, Brown E, Dickens NJ, Hammarton TC, Mottram JC. Regulators of Trypanosoma brucei cell cycle progression and differentiation identified using a kinome-wide RNAi screen.. PLoS Pathog 2014 Jan;10(1):e1003886.
    doi: 10.1371/journal.ppat.1003886pubmed: 24453978pmc: 3894213google scholar: lookup
  11. Kumar R, Jain S, Kumar S, Sethi K, Kumar S, Tripathi BN. Impact estimation of animal trypanosomosis (surra) on livestock productivity in India using simulation model: Current and future perspective.. Vet Parasitol Reg Stud Reports 2017 Dec;10:1-12.
    doi: 10.1016/j.vprsr.2017.06.008pubmed: 31014579google scholar: lookup
  12. Kumar R, Rani R, Kumar S, Sethi K, Jain S, Batra K, Kumar S, Tripathi BN. Drug-induced reactive oxygen species-mediated inhibitory effect on growth of Trypanosoma evansi in axenic culture system.. Parasitol Res 2020 Oct;119(10):3481-3489.
    doi: 10.1007/s00436-020-06861-7pubmed: 32869169google scholar: lookup
  13. Lisk G, Pain M, Gluzman IY, Kambhampati S, Furuya T, Su XZ, Fay MP, Goldberg DE, Desai SA. Changes in the plasmodial surface anion channel reduce leupeptin uptake and can confer drug resistance in Plasmodium falciparum-infected erythrocytes.. Antimicrob Agents Chemother 2008 Jul;52(7):2346-54.
    doi: 10.1128/AAC.00057-08pubmed: 18443109pmc: 2443925google scholar: lookup
  14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.. Methods 2001 Dec;25(4):402-8.
    doi: 10.1006/meth.2001.1262pubmed: 11846609google scholar: lookup
  15. Merritt C, Silva LE, Tanner AL, Stuart K, Pollastri MP. Kinases as druggable targets in trypanosomatid protozoan parasites.. Chem Rev 2014 Nov 26;114(22):11280-304.
    doi: 10.1021/cr500197dpubmed: 26443079pmc: 4254031google scholar: lookup
  16. Mortlock AA, Foote KM, Heron NM, Jung FH, Pasquet G, Lohmann JJ, Warin N, Renaud F, De Savi C, Roberts NJ, Johnson T, Dousson CB, Hill GB, Perkins D, Hatter G, Wilkinson RW, Wedge SR, Heaton SP, Odedra R, Keen NJ, Crafter C, Brown E, Thompson K, Brightwell S, Khatri L, Brady MC, Kearney S, McKillop D, Rhead S, Parry T, Green S. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase.. J Med Chem 2007 May 3;50(9):2213-24.
    doi: 10.1021/jm061335fpubmed: 17373783google scholar: lookup
  17. Morty RE, Lonsdale-Eccles JD, Mentele R, Auerswald EA, Coetzer TH. Trypanosome-derived oligopeptidase B is released into the plasma of infected rodents, where it persists and retains full catalytic activity.. Infect Immun 2001 Apr;69(4):2757-61.
    doi: 10.1128/IAI.69.4.2757-2761.2001pubmed: 11254649pmc: 98221google scholar: lookup
  18. Morty RE, Pellé R, Vadász I, Uzcanga GL, Seeger W, Bubis J. Oligopeptidase B from Trypanosoma evansi. A parasite peptidase that inactivates atrial natriuretic factor in the bloodstream of infected hosts.. J Biol Chem 2005 Mar 25;280(12):10925-37.
    doi: 10.1074/jbc.M410066200pubmed: 15644339google scholar: lookup
  19. Motta FN, Bastos IM, Faudry E, Ebel C, Lima MM, Neves D, Ragno M, Barbosa JA, de Freitas SM, Santana JM. The Trypanosoma cruzi virulence factor oligopeptidase B (OPBTc) assembles into an active and stable dimer.. PLoS One 2012;7(1):e30431.
    doi: 10.1371/journal.pone.0030431pubmed: 22276197pmc: 3261901google scholar: lookup
  20. Naula C, Parsons M, Mottram JC. Protein kinases as drug targets in trypanosomes and Leishmania.. Biochim Biophys Acta Proteins Proteom 1754:151–159.
    doi: 10.1016/j.bbapap.2005.08.018google scholar: lookup
  21. Ota T, Suto S, Katayama H, Han ZB, Suzuki F, Maeda M, Tanino M, Terada Y, Tatsuka M. Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability.. Cancer Res 2002 Sep 15;62(18):5168-77.
    pubmed: 12234980
  22. Pathak KM, Chhabra MB. Parasites and parasitic diseases of the camel in India: a review.. Ind J Anim Sci 80:699–706.
  23. Puttonen KA, Lehtonen S, Raasmaja A, Männistö PT. A prolyl oligopeptidase inhibitor, Z-Pro-Prolinal, inhibits glyceraldehyde-3-phosphate dehydrogenase translocation and production of reactive oxygen species in CV1-P cells exposed to 6-hydroxydopamine.. Toxicol In Vitro 2006 Dec;20(8):1446-54.
    doi: 10.1016/j.tiv.2006.07.001pubmed: 16942854google scholar: lookup
  24. Rani R, Narasimhan B, Varma RS, Kumar R. Naphthoquinone derivatives exhibit apoptosis-like effect and anti-trypanosomal activity against Trypanosoma evansi.. Vet Parasitol 2021 Feb;290:109367.
    doi: 10.1016/j.vetpar.2021.109367pubmed: 33516118google scholar: lookup
  25. Roy N, Nageshan RK, Pallavi R, Chakravarthy H, Chandran S, Kumar R, Gupta AK, Singh RK, Yadav SC, Tatu U. Proteomics of Trypanosoma evansi infection in rodents.. PLoS One 2010 Mar 22;5(3):e9796.
    doi: 10.1371/journal.pone.0009796pubmed: 20339546pmc: 2842431google scholar: lookup
  26. Sharma D, Gupta S, Sethi K, Kumar S, Kumar R. Seroprevalence and immunological characterization of Trypanosoma evansi infection in livestock of four agro-climatic zones of Himachal Pradesh, India.. Trop Anim Hlth Prod 54:1–10.
    doi: 10.1007/s11250-022-03069-ygoogle scholar: lookup
  27. Sirivan C, Pramoolsinsap T, Pemayodhin P. Effect of diminazene aceturate and isometamidium chloride on the control of Trypanosoma evansi in naturally infected sow.. Health Sci J Thai 8:101–109.
  28. Troeberg L, Pike RN, Morty RE, Berry RK, Coetzer TH, Lonsdale-Eccles JD. Proteases from Trypanosoma brucei brucei. Purification, characterisation and interactions with host regulatory molecules.. Eur J Biochem 1996 Jun 15;238(3):728-36.
    doi: 10.1111/j.1432-1033.1996.0728w.xpubmed: 8706674google scholar: lookup
  29. Tu X, Kumar P, Li Z, Wang CC. An aurora kinase homologue is involved in regulating both mitosis and cytokinesis in Trypanosoma brucei.. J Biol Chem 2006 Apr 7;281(14):9677-87.
    doi: 10.1074/jbc.M511504200pubmed: 16436376google scholar: lookup
  30. Tuntasuvan D, Jarabrum W, Viseshakul N, Mohkaew K, Borisutsuwan S, Theeraphan A, Kongkanjana N. Chemotherapy of surra in horses and mules with diminazene aceturate.. Vet Parasitol 2003 Jan 2;110(3-4):227-33.
    doi: 10.1016/s0304-4017(02)00304-7pubmed: 12482651google scholar: lookup
  31. Yadav SC, Kumar P, Khurana S, Kumar R. Seroprevalence of Trypanosoma evansi Infection in Equines of North and North Western States of India.. J Equine Vet Sci 2019 Aug;79:63-67.
    doi: 10.1016/j.jevs.2019.05.019pubmed: 31405503google scholar: lookup

Citations

This article has been cited 0 times.
Subscribe to our newsletter
Join 99,727 horse owners like you who receive our email updates on horse health and nutrition.